Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SanBio, a regenerative medicine company leading the way in the development of cell-based biologics targeting neurological disorders, has been granted a key patent by the US Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, SB623.
Subscribe to our email newsletter
SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for chronic stroke and other debilitating neurological disorders.
United States Patent No. 8,969,078, which covers SB623 cells for all uses, was formally granted on March 3, 2015 and protects the composition of SB623 cells.
This patent strengthens SanBio’s intellectual property protection for SB623, which previously included protection for methods of making the cells and methods of using the cells to treat various conditions of the central nervous system.
SanBio has also received a patent protecting the methods for treating stroke with SB623 cells.
Said Dr. Damien Bates, Chief Medical Officer at SanBio, "Especially during the month of May, National Stroke Awareness month, we reflect on the prevalence of stroke and reaffirm our commitment to developing a therapeutic option for the thousands still suffering from its debilitating effects.
"This patent protection speaks to our confidence in our technology and the use of SB623 cells to promote regenerative healing for neurological disorders such as stroke."